Tag: chronic pruritus therapeutics market size

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Pruritus Therapeutics Market?

The rising prevalence of atopic dermatitis (AD) is expected to drive the growth of the chronic pruritus therapeutics market. Atopic dermatitis is a common chronic inflammatory skin condition that leads to persistent itching, redness, and skin irritation, and its prevalence is growing due to factors such as genetic predisposition, environmental changes, and increased allergen exposure. Chronic pruritus therapeutics target underlying inflammatory pathways to alleviate the persistent itching associated with AD, thereby improving patient comfort and quality of life. According to the International Eczema Council, approximately 223 million people worldwide are living with atopic dermatitis, including 43 million children aged 1-4. The rising prevalence of AD is, therefore, propelling the demand for chronic pruritus therapeutics.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

#What is the Anticipated CAGR of theChronic Pruritus Therapeutics Market, and What Factors Will Drive It?

The chronic pruritus therapeutics market has also shown strong growth in recent years. It is expected to rise from $10.17 billion in 2024 to $10.94 billion in 2025 at a CAGR of 7.6%. The historical growth can be attributed to the increasing prevalence of chronic pruritus, growing demand for effective treatments, an increase in regulatory approvals, more product authorizations, and a rise in mergers, collaborations, and acquisitions among industry participants.

The chronic pruritus therapeutics market is anticipated to grow significantly, reaching $14.49 billion by 2029 at a CAGR of 7.3%. This growth will be fueled by increasing awareness, a rise in atopic dermatitis cases, an expanding focus on personalized medicine, a growing prevalence of dermatological conditions, and an increasing patient population. Major trends shaping this market include the introduction of innovative drugs, the development of novel biologics and targeted therapies, advancements in drug delivery systems, collaborations between pharmaceutical firms and research institutions, and the incorporation of digital health technologies such as telemedicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

What Are the Key Market Innovations in theChronic Pruritus Therapeutics Market Over the Coming Years?

Leading companies in the chronic pruritus therapeutics market are concentrating on developing innovative formulations, such as intravenous (IV) injections, to improve treatment efficacy and offer faster relief for patients. IV injections deliver medications, such as antihistamines or corticosteroids, directly into the bloodstream, quickly alleviating itching and reducing inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based company, announced that its partner company Maruishi Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, received approval from Japan’s Ministry of Health, Labour and Welfare for Korsuva IV injection. This treatment is aimed at pruritus in hemodialysis patients. The approval followed positive Phase 3 clinical trial results, showing significant improvements in itching scores compared to a placebo, with the treatment being well-tolerated by patients. The approval also triggered a $1.5 million milestone payment to Cara Therapeutics, as outlined in their licensing agreement with Maruishi.

Who Are the Top Companies Driving Innovation and Growth in theChronic Pruritus Therapeutics Market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Key Market Segments Comprise the Chronic Pruritus Therapeutics Market and Drive Its Revenue Growth?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Which Regions Are Emerging as Leaders in the Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Pruritus Therapeutics Market?

The rising prevalence of atopic dermatitis (AD) is expected to drive the growth of the chronic pruritus therapeutics market. Atopic dermatitis is a common chronic inflammatory skin condition that leads to persistent itching, redness, and skin irritation, and its prevalence is growing due to factors such as genetic predisposition, environmental changes, and increased allergen exposure. Chronic pruritus therapeutics target underlying inflammatory pathways to alleviate the persistent itching associated with AD, thereby improving patient comfort and quality of life. According to the International Eczema Council, approximately 223 million people worldwide are living with atopic dermatitis, including 43 million children aged 1-4. The rising prevalence of AD is, therefore, propelling the demand for chronic pruritus therapeutics.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

#What is the Anticipated CAGR of theChronic Pruritus Therapeutics Market, and What Factors Will Drive It?

The chronic pruritus therapeutics market has also shown strong growth in recent years. It is expected to rise from $10.17 billion in 2024 to $10.94 billion in 2025 at a CAGR of 7.6%. The historical growth can be attributed to the increasing prevalence of chronic pruritus, growing demand for effective treatments, an increase in regulatory approvals, more product authorizations, and a rise in mergers, collaborations, and acquisitions among industry participants.

The chronic pruritus therapeutics market is anticipated to grow significantly, reaching $14.49 billion by 2029 at a CAGR of 7.3%. This growth will be fueled by increasing awareness, a rise in atopic dermatitis cases, an expanding focus on personalized medicine, a growing prevalence of dermatological conditions, and an increasing patient population. Major trends shaping this market include the introduction of innovative drugs, the development of novel biologics and targeted therapies, advancements in drug delivery systems, collaborations between pharmaceutical firms and research institutions, and the incorporation of digital health technologies such as telemedicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

What Are the Key Market Innovations in theChronic Pruritus Therapeutics Market Over the Coming Years?

Leading companies in the chronic pruritus therapeutics market are concentrating on developing innovative formulations, such as intravenous (IV) injections, to improve treatment efficacy and offer faster relief for patients. IV injections deliver medications, such as antihistamines or corticosteroids, directly into the bloodstream, quickly alleviating itching and reducing inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based company, announced that its partner company Maruishi Pharmaceutical Co. Ltd., a pharmaceutical firm based in Japan, received approval from Japan’s Ministry of Health, Labour and Welfare for Korsuva IV injection. This treatment is aimed at pruritus in hemodialysis patients. The approval followed positive Phase 3 clinical trial results, showing significant improvements in itching scores compared to a placebo, with the treatment being well-tolerated by patients. The approval also triggered a $1.5 million milestone payment to Cara Therapeutics, as outlined in their licensing agreement with Maruishi.

Who Are the Top Companies Driving Innovation and Growth in theChronic Pruritus Therapeutics Market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Key Market Segments Comprise the Chronic Pruritus Therapeutics Market and Drive Its Revenue Growth?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Which Regions Are Emerging as Leaders in the Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the chronic pruritus therapeutics market right now?

The market size of chronic pruritus therapeutics has witnessed considerable growth in the past few years. The market will expand from $10.17 billion in 2024 to $10.94 billion in 2025, marking a compound annual growth rate (CAGR) of 7.6%. This expansion during the historic period emanates from several factors such as an increase in the incidence of chronic pruritus, a surge in demand for viable treatments, climbing regulatory approvals, an upswing in product approvals, plus a rise in mergers, collaborations, and acquisitions amongst key industry players.

How fast Is the chronic pruritus therapeutics market expected to grow, and what’s its future value?

In the forthcoming years, the market size of chronic pruritus therapeutics is projected to expand significantly, reaching $14.49 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during the forecast period include increasing awareness, a rise in atopic dermatitis, a greater emphasis on personalized medicine, a higher incidence of dermatological conditions, and a growing patient population. Major trends identified for the forecast period encompass the introduction of innovative medicines, the creation of novel biologics and targeted therapies, technological advancements, the blending of advanced drug delivery systems, partnerships between pharmaceutical firms and research institutions, and digital health technologies such as telemedicine.

Get your chronic pruritus therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

What are the leading drivers of growth in the chronic pruritus therapeutics market?

The chronic pruritus therapeutics market is poised for growth, propelled by the escalating occurrence of atopic dermatitis. Characterized by inflammatory symptoms such as redness, itching, dryness, and discomfort, atopic dermatitis (AD) commonly impacts those with a familial history of allergies, asthma, or hay fever. Increases in atopic dermatitis can be traced back to aspects like genetic makeup, environmental modifications, lifestyle contributors, the hygiene paradigm, heightened allergen exposure, and imbalances in skin microbiome. Therapeutics for chronic pruritus are designed to mitigate unrelenting itchiness ensuing from atopic dermatitis, by focusing on the inflammation pathways, decreasing skin irritation, and enhancing patient comfort levels. For example, data from the International Eczema Council, a nonprofit organization in the US, showed that around 223 million individuals worldwide were dealing with atopic dermatitis in 2022 (GBD 2022), which includes 43 million kids between the ages of 1-4, illustrating the condition’s notable incidence in early childhood. Consequently, the increasing occurrence of atopic dermatitis is steering the expansion of the chronic pruritus therapeutics market.

What are the key segments defining the chronic pruritus therapeutics market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Who are the key players steering the development of the chronic pruritus therapeutics market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What emerging trends are influencing the growth of the chronic pruritus therapeutics market?

Within the chronic pruritus therapeutics market, dominant businesses are aiming to enhance treatment effectiveness and expedite patient relief by concentrating on the development of innovative formulations like intravenous (IV) injections. IV injections are effective in pruritus treatment as they deliver medications such as antihistamines or corticosteroids directly into the bloodstream, providing rapid itch relief and reducing inflammation. For example, in September 2023, Cara Therapeutics Inc., a U.S.-based therapeutic manufacturing firm, announced that its affiliate, Maruishi Pharmaceutical Co. Ltd, a company based in Japan, obtained approval for the Korsuva IV injection syringe, intended for pruritus treatment in hemodialysis patients, from Japan’s Ministry of Health, Labour and Welfare agency. This approval was granted following favorable Phase 3 clinical trial outcomes conducted jointly by Maruishi and Kissei Pharmaceutical Co., Ltd. This treatment demonstrated considerable enhancements in itch scores compared to a placebo, with patients tolerating it well. Following their licensing agreement with Maruishi, Cara Therapeutics, the developer of Korsuva, will now receive a milestone payment of $1.5 million, courtesy of this approval.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

Which regions are most influential in expanding the chronic pruritus therapeutics market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Chronic Pruritus Therapeutics Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market size of chronic pruritus therapeutics has seen robust growth in the past few years. The predicted growth of this market is set to increase from $10.17 billion in 2024 to $10.94 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. This historical growth is mainly due to the increased prevalence of chronic pruritus, a surge in demand for effective treatment options, an escalation in regulatory approvals, augmented product endorsements, and a rise in the frequency of mergers, collaborations, and acquisitions amongst industry participants.

The market for therapeutics for chronic pruritus is anticipated to experience vigorous growth in the coming years. It’s projected to reach a value of $14.49 billion in 2029, growing at a compound annual growth rate (CAGR) of 7.3%. The projected increase within the forecast period could be ascribed to escalating awareness, upsurge in atopic dermatitis, amplified emphasis on personalized medication, rising instances of dermatological diseases, and an expanding patient population. The predominant trends for the forecast period comprise the introduction of innovative drugs, the development of groundbreaking biologics and targeted treatments, technological advancements, the incorporation of sophisticated drug delivery systems, partnerships between pharmaceutical firms and research institutions, and digital healthcare technologies including telemedicine.

What Drivers Are Shaping the Growth of the Chronic Pruritus Therapeutics Market?

The surge in the number of atopic dermatitis cases is predicted to fuel the expansion of the chronic pruritus therapeutics market in the future. Characterized by inflammation, redness, itchiness, dryness, and discomfort, atopic dermatitis (AD) tends to frequently impact individuals who have a familial history of allergies, asthma, or hayfever. The escalating incidence of atopic dermatitis can be traced back to elements such as genetic tendencies, alterations in the environment, lifestyle influences, the hygiene hypothesis, elevated exposure to allergens, and imbalances in the skin’s microbiome. Chronic pruritus therapeutics help relieve the unwavering itching linked with atopic dermatitis by addressing the root inflammatory pathways, minimizing skin inflammation, and elevating patient comfort. For example, the International Eczema Council, a non-profit organization based in the US, revealed in 2022 that approximately 223 million individuals around the world were diagnosed with atopic dermatitis (GBD 2022), 43 million of whom are children between 1-4 years old. This data underscores the significant prevalence of the condition in early youth. Consequently, the escalating prevalence of atopic dermatitis is leading to the expansion of the chronic pruritus therapeutics market.

Request Your Free Chronic Pruritus Therapeutics Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Who Are the Influential Players Reshaping the Chronic Pruritus Therapeutics Market Landscape?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What New and Evolving Trends Are Having a Lasting Impact on the Chronic Pruritus Therapeutics Market?

Major firms active in the chronic pruritus therapeutics market are currently oriented toward innovation with an emphasis on developing novel solutions such as intravenous (IV) injections to boost therapeutic effectiveness and deliver more immediate relief for patients. This process works by thrusting drugs, including antihistamines or corticosteroids, into the bloodstream to expeditiously relieve itching and minimize inflammation. For instance, in September 2023, the US firm Cara Therapeutics Inc., known for manufacturing therapeutics, announced that its ally firm, Maruishi Pharmaceutical Co. Ltd., based in Japan got the authorization for Korsuva IV injection syringe, a pruritus treatment for hemodialysis patients, from the Japan’s Ministry of Health, Labour and Welfare, a Japanese governmental agency. This green light was given in light of favorable results from Phase 3 clinical trials conducted by Maruishi in partnership with Kissei Pharmaceutical Co., Ltd. The treatment notably improved itching scores against a placebo and was well received by patients. This approval additionally set off a $1.5 million milestone payment to Cara Therapeutics, the creator of Korsuva, as outlined in their agreement with Maruishi.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Key Segments Stand Out in Understanding the Composition of the Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Which Geographic Locations Are Critical to the Growth of the Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Chronic Pruritus Therapeutics Market?

Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Pediatric Bladder Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: